Idiopathic Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Idiopathic Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-10-11FDA Approved: PIRFENIDONE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for pirfenidone from Amneal Pharmaceuticals NY LLC, supporting a generic version of the drug.
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Investigating Idiopathic Pulmonary Fibrosis in Greece
A completed clinical trial investigating idiopathic pulmonary fibrosis with results posted in 2022.
-
FDA approval · 2022-09-21FDA Approved: PIRFENIDONE — Original Application (Camber Pharmaceuticals, Inc.)
Camber Pharmaceuticals received FDA approval for a generic pirfenidone product via an Original Application (ANDA) to treat idiopathic pulmon…
-
CLINICAL_TRIALS trial_result · 2022-09-08Clinical Trial Update: A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 open-label and crossover study investigating belumosudil for idiopathic pulmonary fibrosis has completed and results posted.
-
FDA approval · 2022-08-11FDA Approved: PIRFENIDONE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for pirfenidone from Teva Pharmaceuticals, Inc., supporting a generic version of the drug.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-08-01FDA Approved: PIRFENIDONE — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original application for pirfenidone as a generic product manufactured by ScieGen Pharmaceuticals for idiopathic pulmonary …
-
FDA approval · 2022-08-01FDA Approved: PIRFENIDONE — Original Application (Cipla USA Inc.)
FDA approved an original generic application for pirfenidone by Cipla USA Inc., making a generic version available for idiopathic pulmonary …
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care [Phase 3]
Phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis was terminated.
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care [Phase 3]
Phase 3 trial of GLPG1690 plus standard of care in idiopathic pulmonary fibrosis was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Self-monitoring of Spirometry & Symptoms Via patientMpower App in Idiopathic Pulmonary Fibrosis
A terminated clinical trial evaluating self-monitoring of spirometry and symptoms via the patientMpower app in idiopathic pulmonary fibrosis…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of AK3280 in idiopathic pulmonary fibrosis.
-
FDA approval · 2022-07-19FDA Approved: PIRFENIDONE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved an original application for pirfenidone from ANI Pharmaceuticals, establishing a generic version of the antifibrotic for id…
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough [Phase 2]
Phase 2 trial evaluating NP-120 for idiopathic pulmonary fibrosis shows results on efficacy, safety, and tolerability.
-
FDA approval · 2022-07-19FDA Approved: PIRFENIDONE — Original Application (Laurus Labs Limited)
FDA approved the original application for a generic pirfenidone (Laurus Labs Limited), enabling generic availability for idiopathic pulmonar…
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis [Phase 3]
Phase 3 clinical trial update evaluating cyclophosphamide for acute exacerbation of idiopathic pulmonary fibrosis has completed.
-
FDA approval · 2022-06-13FDA Approved: PIRFENIDONE — Original Application (Sandoz Inc)
The FDA approves Sandoz Inc's original application for pirfenidone, enabling a generic version of the drug to enter the market.
-
FDA approval · 2022-05-24FDA Approved: PIRFENIDONE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved an Abbreviated New Drug Application for pirfenidone (Novadoz Pharmaceuticals LLC), a generic version of the IPF therapy.
-
FDA approval · 2022-05-20FDA Approved: PIRFENIDONE — Original Application (Alembic Pharmaceuticals Limited)
FDA approves Alembic Pharmaceuticals Limited's original application for pirfenidone, establishing a generic version of the antifibrotic medi…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
Phase 2 trial update for Cudetaxestat in idiopathic pulmonary fibrosis (IPF) evaluating efficacy and safety.
-
FDA approval · 2022-05-18FDA Approved: PIRFENIDONE — Original Application (Micro Labs Limited)
FDA approved a generic version of pirfenidone from Micro Labs Limited through an Original Application (ANDA) for idiopathic pulmonary fibros…
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) [Phase 1]
Phase 1 pilot trial of herpesvirus treatment in idiopathic pulmonary fibrosis completed; results posted.
-
FDA approval · 2022-04-28FDA Approved: PIRFENIDONE — Original Application (Sandoz Inc)
The FDA approved Sandoz Inc's original application for a generic pirfenidone product for treatment of idiopathic pulmonary fibrosis.
-
FDA approval · 2022-03-25FDA Approved: PIRFENIDONE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original application for pirfenidone by Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2022-02-11FDA Approved: ESBRIET — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Esbriet (pirfenidone) from Genentech, resulting in labeling changes for the product.
-
FDA approval · 2022-01-25FDA Approved: PIRFENIDONE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved the original application for pirfenidone from Teva Pharmaceuticals, authorizing a generic version for idiopathic pulmonary fibr…